DE69937650D1 - Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe - Google Patents

Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe

Info

Publication number
DE69937650D1
DE69937650D1 DE69937650T DE69937650T DE69937650D1 DE 69937650 D1 DE69937650 D1 DE 69937650D1 DE 69937650 T DE69937650 T DE 69937650T DE 69937650 T DE69937650 T DE 69937650T DE 69937650 D1 DE69937650 D1 DE 69937650D1
Authority
DE
Germany
Prior art keywords
controlled release
bupropion hydrochloride
release tablets
hydrochloride containing
containing controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69937650T
Other languages
English (en)
Other versions
DE69937650T2 (de
Inventor
Pawan Seth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant International Bermuda
Original Assignee
Biovail Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Corp filed Critical Biovail Corp
Application granted granted Critical
Publication of DE69937650D1 publication Critical patent/DE69937650D1/de
Publication of DE69937650T2 publication Critical patent/DE69937650T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69937650T 1998-10-30 1999-10-07 Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe Expired - Lifetime DE69937650T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US184096 1998-10-30
US09/184,096 US6033686A (en) 1998-10-30 1998-10-30 Controlled release tablet of bupropion hydrochloride

Publications (2)

Publication Number Publication Date
DE69937650D1 true DE69937650D1 (de) 2008-01-10
DE69937650T2 DE69937650T2 (de) 2008-07-17

Family

ID=22675529

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69937650T Expired - Lifetime DE69937650T2 (de) 1998-10-30 1999-10-07 Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe
DE69917866T Expired - Lifetime DE69917866T2 (de) 1998-10-30 1999-10-07 Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69917866T Expired - Lifetime DE69917866T2 (de) 1998-10-30 1999-10-07 Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe

Country Status (5)

Country Link
US (1) US6033686A (de)
EP (2) EP1232747B1 (de)
AT (1) ATE268593T1 (de)
DE (2) DE69937650T2 (de)
ES (2) ES2295256T3 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US20030203055A1 (en) * 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
IN192747B (de) * 2002-04-15 2004-05-15 Ranbaxy Lab Ltd
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
WO2004067039A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20040162320A1 (en) * 2003-02-14 2004-08-19 Pawan Seth Solid composition containing nisoldipine a mixture of polyethylene oxides and an antioxidant
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
AP1899A (en) * 2003-08-08 2008-10-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
EP1523979A1 (de) * 2003-10-13 2005-04-20 Wyeth Darreichungsform mit verlängerter Freisetzung
WO2005049003A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Extended release dosage forms of bupropion hydrochloride
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US8586085B2 (en) * 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
KR100670798B1 (ko) 2004-12-17 2007-01-17 한국전자통신연구원 데이터베이스 캐시 시스템
EP2502621A1 (de) * 2005-06-27 2012-09-26 Valeant International (Barbados) SRL Kristalline Formen von Bupropion HBr
US7645802B2 (en) * 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
EP2135603B1 (de) * 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Zusammensetzungen und Verfahren zur Erhöhung der Insulinsensitivität
ES2383330T3 (es) * 2005-11-28 2012-06-20 Orexigen Therapeutics, Inc. Formulación de liberación sostenida de zonisamida
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
BRPI0715959A2 (pt) * 2006-08-21 2013-07-30 Jubilant Organosys Ltd composiÇço farmacÊutica de liberaÇço modificada de cloridrato de bupropion
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
KR20180066272A (ko) 2006-11-09 2018-06-18 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
AU2008266906A1 (en) * 2007-06-18 2008-12-24 The General Hospital Corporation Combination therapy for depression
MX2010012909A (es) * 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
CN102105140B (zh) * 2008-07-02 2013-10-23 巴斯夫欧洲公司 涂覆片剂的方法
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
RU2616496C2 (ru) 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
WO2013184837A1 (en) 2012-06-06 2013-12-12 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
JPH0759499B2 (ja) * 1984-02-10 1995-06-28 ベンツォン ファーマ エイ／エス 拡散被覆された複合単位服用剤
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
DE3486409T2 (de) * 1984-08-17 1996-04-25 Wellcome Found Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer

Also Published As

Publication number Publication date
EP1232747A3 (de) 2003-01-29
EP1232747A2 (de) 2002-08-21
US6033686A (en) 2000-03-07
EP1004298A3 (de) 2000-06-14
EP1004298B1 (de) 2004-06-09
DE69917866D1 (de) 2004-07-15
DE69937650T2 (de) 2008-07-17
ES2222020T3 (es) 2005-01-16
EP1004298A2 (de) 2000-05-31
ATE268593T1 (de) 2004-06-15
ES2295256T3 (es) 2008-04-16
EP1232747B1 (de) 2007-11-28
DE69917866T2 (de) 2005-07-07

Similar Documents

Publication Publication Date Title
DE69937650D1 (de) Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe
MEP3608A (en) Modified-release tablet of bupropion hydrochloride
ATE412437T1 (de) Silber enthaltende zusammensetzungen, geräte und verfahren zu deren herstellung
WO2002024174A3 (en) Sustained release composition containing clarithromycin
PL370793A1 (en) Gastric retention controlled drug delivery system
WO2002072033A3 (en) Chronotherapeutic dosage forms containing glucocorticosteroid
ATE173893T1 (de) Matrizen mit verzögerter freisetzung für dentalzwecke
ATE376587T1 (de) Granulat mit hoher schlagfestigkeit
WO2004108067A3 (en) Programmed drug delivery system
DK0868912T3 (da) Anvendelse af redispergerbare polymerpulvere eller polymergranulater til coating af farmaceutiske eller agrokemiske applikationsformer
NO20016108L (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
CA2346341A1 (en) Encapsulated chemicals for use in controlled time release applications and methods
CA2262068A1 (en) Water-soluble or water-swellable copolymers containing sulfonic groups, methods of preparing them, and applications
BR0215397A (pt) Pensos cirúrgicos revestidos
GEP20074048B (en) Sustained-release tablet composition of pramipexole
DZ3191A1 (fr) Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci.
AU2002254036A1 (en) Taste masked pharmaceutical compositions
TR199902773A3 (tr) Sikistirilmis granül, üretimi ve sulama maddesi olarak kullanimi.
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
CA2324493A1 (en) Controlled release oral tablet having a unitary core
ES2134944T3 (es) Agente anticorrosivo de plata ii.
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
BR0201905A (pt) Composições para revestimento por imersão contendo amido ou dextrina
WO2005027843A3 (en) Chronotherapeutic dosage forms

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BIOVAIL LABORRATORIES INTERNATIONAL S.R.L., CO, BB

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1232747

Country of ref document: EP

Representative=s name: UEXKUELL & STOLBERG, DE

R081 Change of applicant/patentee

Ref document number: 1232747

Country of ref document: EP

Owner name: VALEANT INTERNATIONAL (BARBADOS) SRL, BB

Free format text: FORMER OWNER: BIOVAIL LABORRATORIES INTERNATIONAL S.R.L., COLLYMORE ROCK, BB

Effective date: 20121017

R082 Change of representative

Ref document number: 1232747

Country of ref document: EP

Representative=s name: UEXKUELL & STOLBERG, DE

Effective date: 20121017